Dr. Endrész Valéria

Email: endresz.valeria@med.u-szeged.hu

Phone: +36 62 545 541

* * *

Focus of our research

• - Investigation of antigens that have atheroprotective immunogenic capability with immune
  
  
• - Investigation of atherosclerosis-modulating effect of Chlamydia pneumoniae infection
  
  
• - In vitro characterization of the mechanism of cell type-specific replication of chlamydiae
  
  

In cooperation with The Thrombosis Research institute, London, Uk, we do atherosclerosis vaccine research. We immunize atherosclerosis-prone mouse strains with recombinant antigenic constructs carrying potential atheroprotective epitopes. Immune cells are isolated from the immunized animals and adoptive transfer of these cells is used for elucidation of the mechanism of atheroprotective effect. Two mouse strains with lipid metabolism-related genetic modifications are used for the investigation of the association of Chlamydia pneumoniae infection and atherosclerosis development. Histologic and gene-expression approach is applied in the evaluation of mouse tissues. We study the host cell type-specific replication strategy of different Chlamydia species by analysing the expression pattern of chlamydial genes.

Selected publications

• Xia M, Chen D, Endresz V, Lantos I, Szabo A, Kakkar V, Lu:
  X Modulation of recombinant Antigenic constructs containing multi-epitopes towards effective reduction of atherosclerotic lesion in B6;129S-Ldlrtm1HerApobtm2Sgy/J mice PLOS ONE 10:(4) pp. 1-21. (2015)


• Xia M, Chen D, Endresz V, Faludi I, Szabo A, Gonczol E, Kakkar V, Lu X:
  Immunization of Chlamydia pneumoniae (Cpn)-Infected Apob(tm2Sgy)Ldlr(tm1Her)/J Mice with a Combined Peptide of Cpn Significantly Reduces Atherosclerotic Lesion Development. PLOS ONE 8:(12) pp. 1-12. (2013)


• Lu XJ, Xia M, Endresz V, Faludi I, Mundkur L, Gonczol E, Chen DX, Kakkar:
  VV Immunization With a Combination of 2 Peptides Derived From the C5a Receptor Significantly Reduces Early Atherosclerotic Lesion in Ldlr(tm1Her) Apob(tm2Sgy)J Mice ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 32:(10) pp. 2358-2371. (2012)


• Kari L, Goheen M M, Randall L B, Taylor L D, Carlson J H, Whitmire W M, Virok D, Rajaram K, Endresz V, McClarty G, Nelson D E, Caldwell:
  H D Generation of targeted chlamydia trachomatis null mutants PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 108:(17) pp. 7189-7193. (2011)


• Faludi I, Burian K, Csanadi A, Miczak A, Lu XJ, Kakkar VV, Gonczol E, Endresz V:
  Adjuvant modulation of the immune response of mice against the LcrE protein of Chlamydophila pneumoniae INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY 299:(7) pp. 520-528. (2009)


• Burian K, Kis Z, Virok D, Endresz V, Prohaszka Z, Duba J, Berencsi K, Boda K, Horvath L, Romics L, Fust G, Gonczol E:
  Independent and joint effects of antibodies to human heat-shock protein 60 and Chlamydia pneumoniae infection in the development of coronary atherosclerosis CIRCULATION 103: pp. 1503-1508. (2001)


• Endresz V, Burian K, Berencsi K, Gyulai Z, Kari L, Horton H, Virok D, Meric C, Plotkin S A, Gonczol E:
  Optimization of DNA immunization against human cytomegalovirus VACCINE 19:(28-29) pp. 3972-3980. (2001)


• Gyulai Z, Endresz V, Burian K, Pincus S, Toldy J, Cox W I, Meric C, Plotkin S, Gonczol E, Berencsi K:
  Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-exon4, gB, pp150, and pp28 in healthy individuals: Reevaluation of prevalence of IE1-specific CTLs JOURNAL OF INFECTIOUS DISEASES 181: pp. 1537-1546. (2000)


• Endresz V, Kari L, Berencsi K, Kari C, Gyulai Z, Jeney C, Pincus S, Rodeck U, Meric C, Plotkin SA, Gonczol E:
  Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization VACCINE 17:(1) pp. 50-58. (1999)